The Center for International Blood and Marrow Transplant Research (CIBMTR) is a clinical research program dedicated to addressing important issues in hematopoietic cell transplantation (HCT) by offering a unique resource of data and statistical expertise to the scientific community. The CIBMTR includes > 400 HCT centers that share data on HCT outcomes and a Statistical Center that maintains a clinical database with information for more than 250,000 HCT recipients. These data and the analytic support available through the CIBMTR Statistical Center have led to successful completion of hundreds of studies. U24-CA76518 provides the primary support for these activities. This application requests funding for the next 5 years to support this resource in order to provide the biomedical community continued access to a high quality clinical database and statistical support to facilitate clinical research. Planned resource enhancements include development of electronic data acquisition technology to facilitate participation by a wide range of U.S. and non-U.S. HCT centers; collaboration with other domestic and international organizations to increase the data available to study transplantation for rare indications and new HCT technologies; collecting data on outcome of other therapeutic applications of hematopoietic stem cells; expanding data on late effects and long-term quality of life; and developing new biostatistical methodology to address the challenges, needs and opportunities in analyzing HCT outcomes. The CIBMTR is committed to meeting the needs of investigators in a rapidly evolving field. It has and will build on the infrastructure made possible by support from U24-CA76518 and partnership with others to better serve the research community. Activities during the current and previous funding cycles have led to not only many publications on important issues in HCT but also have created the opportunity for greatly expanded global collaboration in data exchange and observational HCT research and contributed substantially to the success of a U.S. multicenter clinical trials network in HCT. Enhancements already in progress and planned for the next funding cycle will allow more in-depth exploration of immunobiologic aspects of HCT and post-HCT QOL. In summary, the CIBMTR, with the support provided through U24-CA76518, continues to play a unique role in facilitating clinical research in HCT. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
2U24CA076518-11
Application #
7476626
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (J1))
Program Officer
Merritt, William D
Project Start
1998-03-01
Project End
2013-02-28
Budget Start
2008-06-27
Budget End
2009-02-28
Support Year
11
Fiscal Year
2008
Total Cost
$3,082,752
Indirect Cost
Name
Medical College of Wisconsin
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Inamoto, Yoshihiro; Petri?ek, Igor; Burns, Linda et al. (2018) Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Biol Blood Marrow Transplant :
Sahebi, Firoozeh; Garderet, Laurent; Kanate, Abraham S et al. (2018) Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biol Blood Marrow Transplant :
Pulsipher, Michael A; Logan, Brent R; Kiefer, Deidre M et al. (2018) Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors. Haematologica :
Jacobsohn, David A; Loken, Michael R; Fei, Mingwei et al. (2018) Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biol Blood Marrow Transplant 24:2040-2046
Lund, Troy C; Ahn, Kwang Woo; Tecca, Heather R et al. (2018) Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant :
Nemecek, Eneida R; Hilger, Ralf A; Adams, Alexia et al. (2018) Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood Biol Blood Marrow Transplant 24:1651-1656
Rice, Carmel; Eikema, Dirk-Jan; Marsh, Judith C W et al. (2018) Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biol Blood Marrow Transplant :
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Ustun, Celalettin; Young, Jo-Anne H; Papanicolaou, Genovefa A et al. (2018) Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant :
Scott, Emma C; Hari, Parameswaran; Kumar, Sathish et al. (2018) Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant 24:2443-2449

Showing the most recent 10 out of 641 publications